Skip to main content
REGN
NASDAQ Life Sciences

辉瑞中期Tilrekimig数据对雷金纳顿的迪普西恩构成威胁，股价下跌

feedReported by Wiseek News
Sentiment info
Negative
Importance info
7
Price
$774.66
Mkt Cap
$81.884B
52W Low
$476.487
52W High
$821.11
Market data snapshot near publication time

summarizeSummary

雷金纳顿的股价在辉瑞宣布Tilrekimig中期数据后，预市交易中下跌约1.2%。Tilrekimig是雷金纳顿热销药物迪普西恩的潜在竞争对手。辉瑞预计2027-28年公布晚期结果。另外，雷金纳顿通过在神经学和眼科领域添加新项目来扩大其开发portfolio。虽然pipeline扩张是一个长期的积极战略举动，但立即的市场反应是由对迪普西恩的竞争威胁驱动的，迪普西恩是雷金纳顿的关键收入驱动因素。这个消息引入了一个新的负面催化剂，与雷金纳顿其他pipeline资产的最近积极发展形成对比。交易者将密切关注辉瑞的Tilrekimig进展以及雷金纳顿新治疗项目的任何进一步细节。

在该公告发布时，REGN的交易价格为$774.66，交易所为NASDAQ，所属行业为Life Sciences，市值约为$818.8亿。 52周交易区间为$476.49至$821.11。 这则新闻被评估为消极市场情绪，重要性评分为7/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:54 AM EDT
Filing Type: 10-Q
Importance Score:
8
Regeneron Reports Mixed Q1 Results, Authorizes $3B Buyback, Details Government Pricing Deals & Key Legal Updates
Sentiment: Neutral
View Wiseek Article
REGN
Apr 29, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
Sentiment: Positive
View Wiseek Article
REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
Sentiment: Positive
View Wiseek Article
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
FDA Approves Regeneron's Gene Therapy for Inherited Deafness
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
Sentiment: Positive
View Wiseek Article
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Gains U.S. Approval for Young Children with Chronic Spontaneous Urticaria
Sentiment: Positive
View Wiseek Article
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
Sentiment: Positive
View Wiseek Article
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
Sentiment: Positive
View Wiseek Article
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
Sentiment: Positive
View Wiseek Article